Fortress Biotech Quote - FBIO

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.57

Bid

1.55

Offer

1.70

Volume

0.00 Day's Range 0.00

1.355 52 Week Range 4.43

Market Cap

43.34M

Previous Close

1.57

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

613,121

Shares Outstanding

27,604,934

Dividend Yield

PE Ratio

-0.63

Earnings Per Share (EPS)

-2.49

Revenue

84.51M

Net Profit

-68.67M

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the g... Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.fortressbiotech.com

Headquarters

Dover, Delaware, USA

Founded

Fortress Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FBIO. The last closing price for Fortress Biotech was US$1.57. Over the last year, Fortress Biotech shares have traded in a share price range of US$ 1.355 to US$ 4.43.

Fortress Biotech currently has 27,604,934 shares in issue. The market capitalisation of Fortress Biotech is US$43.34 million. Fortress Biotech has a price to earnings ratio (PE ratio) of -0.63.

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or...

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of...

Mustang Bio Receives Positive Listing Determination from Nasdaq

WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1...

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.065	-3.9755351682	1.635	1.635	1.41	494198	1.51268398	CS
4	-0.2	-11.2994350282	1.77	2.1	1.41	587824	1.7615855	CS
12	-0.48	-23.4146341463	2.05	2.1	1.355	613121	1.64697158	CS
26	-0.41	-20.7070707071	1.98	2.89	1.355	411847	1.75983971	CS
52	-1.26	-44.5229681979	2.83	4.43	1.355	422838	2.03872511	CS
156	-44.48	-96.5906623236	46.05	46.725	1.24	491850	10.34326612	CS
260	-26.18	-94.3423423423	27.75	91.5	1.24	656920	34.07592602	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	0
AACGATA Creativity Global	US$ 1.02 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	0
AACGATA Creativity Global	US$ 1.02 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	0
AACGATA Creativity Global	US$ 1.02 (0.00%)	0